Asset
TANRUPRUBART
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04035135 | phase1 | completed | 2020-01-29 | 2021-05-19 | Annexon, Inc. | A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) |
| NCT07020819 | phase3 | recruiting | 2025-09-12 | 2026-12-31 | Annexon, Inc. | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) |
| NCT04514367 | phase2 | completed | 2020-09-29 | 2022-08-29 | Annexon, Inc. | An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease |
| NCT04701164 | phase3 | completed | 2020-12-17 | 2024-04-20 | Annexon, Inc. | Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome |
| NCT04691570 | phase2 | completed | 2021-11-10 | 2023-01-17 | Annexon, Inc. | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) |
FDA applications (0)
This company has no applications containing this asset.